• Bafilomycin C1 in Mechanism-Aware Cell Research

  2026-10-06

  Bafilomycin C1 is described by APExBIO as a vacuolar H+-ATPases inhibitor used to investigate acidic organelle biology. This overview compares its mechanistic rationale with published high-content cardiotoxicity research, emphasizing conceptual applications, evidence strength, interpretation limits, and the lack of direct Bafilomycin C1-specific findings in the supplied study.

• Tunicamycin in ER Stress and Inflammation Research

  2026-10-06

  Tunicamycin is a research-use N-glycosylation inhibitor commonly used as an endoplasmic reticulum stress inducer. This overview compares supplier-reported macrophage findings with a 2025 FASEB Journal study linking UPR-regulated ATF6 to endothelial inflammation after hepatectomy, while emphasizing model-specific evidence, mechanistic limits, and translational boundaries.

• Anti Reverse Cap Analog: Evidence and Limits

  2026-10-05

  A source-grounded overview of Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, explaining its molecular rationale, what the available evidence does and does not establish, and how an OLIG2 synthetic mRNA study should be interpreted without extending preclinical findings into clinical claims.

• Coronavirus Macrodomains and PARP-Mediated Restriction

  2026-10-05

  Grunewald and colleagues showed that coronavirus macrodomains counter a host antiviral pathway involving PARP12 and PARP14, linking ADP-ribosylation to both viral restriction and interferon regulation. The study is significant because pharmacologic and genetic evidence converged on a mechanism in which macrodomain-defective coronavirus becomes more vulnerable to PARP activity, although the findings do not establish a universal mechanism across all coronaviruses or tissues.

• LG 101506: RXR Research Context and Evidence

  2026-10-04

  A source-grounded overview of LG 101506 as a supplier-described RXR modulator, its relevance to nuclear receptor signaling, and the limits of connecting it to published triple-negative breast cancer immunotherapy findings.

• EZ Cap™ Cre mRNA (m1Ψ) Workflow Guide

  2026-10-02

  Build transient, loxP-directed recombination assays with efficiently translated Cre recombinase mRNA while preserving experimental flexibility. This guide connects product handling, delivery-platform benchmarking, extrahepatic targeting concepts, and practical troubleshooting.

• Cx43/NF-κB Signaling in AngII Macrophage Polarization

  2026-10-01

  Wu et al. showed that angiotensin II drives RAW264.7 macrophages toward a pro-inflammatory M1 phenotype through a connexin 43–NF-κB/p65 axis. Pharmacological inhibition of NF-κB or Cx43 reduced inflammatory markers, positioning Cx43 as a mechanistic contributor to AngII-associated macrophage activation and a potential target for cardiovascular inflammation research.

• Imatinib hydrochloride: Assay Workflows & Optimization

  2026-10-01

  Build more reliable kinase-driven cancer assays with a workflow that connects dose response, target engagement, and orthogonal phospho-signaling readouts. This guide also shows how recent kinase–phosphatase findings can sharpen assay interpretation without overextending evidence beyond imatinib’s validated targets.

• 3-Hydroxybutyrate (BHBA): From Metabolite to Mechanism

  2026-09-30

  3-hydroxybutyrate (BHBA) is more than a ketosis marker: it is a metabolic, membrane-active, and epigenetic research probe. This article presents an assay-centered framework for separating direct BHBA effects from broader ketone-body and ischemic-conditioning responses.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-30

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and metabolic responses. It is appropriate for mechanistic preclinical workflows but should not be used to support clinical efficacy conclusions or protocols requiring aqueous or ethanol solubility.

• DeferoxamineB in Iron-Dependent Cancer Assays

  2026-09-29

  DeferoxamineB provides a controllable iron-chelation axis for separating iron-dependent stress from copper-associated, apoptotic, and autophagic effects in cancer models. This workflow shows how to combine dose-response testing, orthogonal cell-death readouts, and metabolic controls without mistaking chelation-based rescue for proof of a single death pathway.

• Sulfo-NHS-SS-Biotin for GlycoRNA Surface Maps

  2026-09-29

  Discover how Sulfo-NHS-SS-Biotin can support reversible cell-surface protein profiling around glycoRNA–RNA-binding protein domains. This article translates recent surface-biology findings into assay design, controls, and interpretation strategies for more defensible interactome studies.

• Ciprofloxacin in Plasmid-Mediated AMR Research

  2026-09-28

  Ciprofloxacin can do more than benchmark antibacterial activity: it can help researchers separate resistance phenotype, gene carriage, plasmid transfer, and clonal spread. This article translates recent carbapenem-resistant Enterobacter cloacae findings into a practical assay-design framework.

• Vincristine Sulfate: Practical Cancer Assay Guide

  2026-09-28

  Use Vincristine sulfate to probe microtubule disruption and antiproliferative responses across cancer models, with a workflow that separates drug handling, dose selection, and orthogonal readouts. The guide turns reported potency into a practical starting point while emphasizing vehicle controls, model-specific optimization, and limits on cross-domain interpretation.

• Mitochondrial Calcium Signaling Represses Ferroptosis

  2026-09-27

  The study links mitochondrial calcium uptake through MCU to acetyl-CoA-dependent GPX4 acetylation, identifying a metabolic route that sustains resistance to ferroptotic cell death. Its mouse, mechanistic, and tumor-model findings suggest testable connections between mitochondrial metabolism and ferroptosis, while leaving the clinical and compound-specific implications open.

8078 records 1/539 page Next 12345 下5页 Last page